Axsome Therapeutics AXSM Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's long-term debt?
- Axsome Therapeutics (AXSM) reported long-term debt of $117.85M in Q1 2026.
- How has Axsome Therapeutics's long-term debt changed year-over-year?
- Axsome Therapeutics's long-term debt decreased by 35.0% year-over-year, from $181.38M to $117.85M.
- What is the long-term trend for Axsome Therapeutics's long-term debt?
- Over 5 years (2020 to 2025), Axsome Therapeutics's long-term debt has grown at a 19.5% compound annual growth rate (CAGR), from $48.32M to $117.75M.
- What does long-term debt mean?
- Total debt that is not due for at least one year.
- How do you interpret long-term debt?
- High levels increase financial leverage and interest expense, while low levels indicate a conservative capital structure.
- How does long-term debt compare across companies?
- Standard metric for assessing capital structure across all public companies.